MedPath

eurodevelopmental Outcome after Fetal Neonatal Alloimmune Thrombocytopenia

Completed
Conditions
antibodies against platelets during pregnancy.
Fetal neonatal alloimmune thrombocytopenia (FNAIT)
10035534
10016849
10012562
Registration Number
NL-OMON49430
Lead Sponsor
eids Universitair Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
63
Inclusion Criteria

- Children diagnosed with FNAIT during pregnancy or postnatal, at moment of
inclusion 2 to 16 years of age.
- Children living in the Netherlands.
- Parents or guardian aged * 18 years old, with parental authority.
- Written informed consent form both parents with, form being approved by
Ethic Committee.

Exclusion Criteria

- Children born with congenital and/or chromosomal abnormalities.
- Children that passed away before inclusion.

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The primary outcome is cognitive development i.e., cognitive test score or<br /><br>Intelligence Quotient (IQ). </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Secondary outcome is neurodevelopmental impairment (NDI); a composite outcome<br /><br>including cerebral palsy Gross Motor Functioning Classification System (GMFCS)<br /><br>* II, cognitive and/or motor test score of less than 70 (-2 SD), hearing loss<br /><br>requiring amplification or visual impairment (legally certifiable as blind or<br /><br>partially sighted). Other secondary outcome parameters are HRQoL and behavioral<br /><br>functioning and the academic performance. The proportion of children with an<br /><br>abnormal course or incidence of infections, asthma, eczema and allergies will<br /><br>be assessed.</p><br>
© Copyright 2025. All Rights Reserved by MedPath